First-in-Class vs Me-Too Launch Differences and the Role of Content, Hyperpersonalization, and Technology with Frank Dolan, Founder and CEO of ARSENAL
October 26, 2022
First-in-class medications are often referred to as innovative treatment alternatives. But innovation might scare and push away some HCPs and patients. In this episode of Pharma Launch Secrets, Bozidar is joined by Frank Dolan, Founder, and CEO of ARSENAL
Pharma/AOR Executives: Make sure you grab a complimentary copy of our 3-Step Guide To Using the Netflix-Like Content Hubs to Engage HCPs in 30-90 Days 👉 3-Step Free Guide
In this episode, Bozidar is joined by Frank Dolan, Founder and CEO of ARSENAL.
- How are first-in-class launches distinct from me-too launches?
- Why is it so hard to access HCPs and launch products successfully?
- What are the opportunities for 1st-time launchers to have successful launches despite reduced access to HCPs?
- Will pharma encourage or discourage peer-to-peer scientific exchange online?
And connect with the host and guest here:
About The Show:
“Pharma Launch Secrets” is a podcast by Evermed and hosted by CEO Bozidar Jovicevic. We host direct, actionable conversations with world-leading pharma launch experts and help you stay up-to-date with the latest trends and strategies to help you launch your product successfully.
Check out our three most downloaded episodes:
If you are interested in joining Pharma Launch Secrets as a guest, please complete this form: http://fame.so/pls-guest
Pharma Launch Secrets is handcrafted by our friends over at fame.so